Lyell Immunopharma (LYEL) Total Liabilities (2020 - 2026)
Lyell Immunopharma (LYEL) posted Total Liabilities of $77.0 million for Q1 2026, down 16.21% sequentially from $91.8 million in Q4 2025, and down 17.49% YoY from $93.3 million in Q1 2025.
Lyell Immunopharma (LYEL) Total Liabilities (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Total Liabilities for 7 years, with the latest figure at $77.0 million in Q1 2026.
- Quarterly Total Liabilities fell 17.49% year-over-year to $77.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.0 million (down 17.49% YoY) and the FY2025 annual result came in at $91.8 million, down 14.98% from the prior year.
- Total Liabilities fell to $77.0 million in Q1 2026 per LYEL's latest filing, from $91.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $190.9 million in Q1 2022 and troughed at $77.0 million in Q1 2026.
- A 5-year average of $105.7 million and a median of $95.1 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities slumped 49.37% in 2023, then increased 13.63% in 2024.
- Over 5 years, Total Liabilities stood at $104.3 million in 2022, then retreated by 8.85% to $95.1 million in 2023, then increased by 13.63% to $108.0 million in 2024, then dropped by 14.98% to $91.8 million in 2025, then fell by 16.21% to $77.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $77.0 million, $91.8 million, and $78.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 77.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.34 Mn |
| Mar 31, 2026 | 76.96 Mn |
| Dec 31, 2025 | 91.85 Mn |
| Sep 30, 2025 | 78.84 Mn |
| Jun 30, 2025 | 86.53 Mn |
| Mar 31, 2025 | 93.28 Mn |
| Dec 31, 2024 | 108.04 Mn |
| Sep 30, 2024 | 88.52 Mn |
| Jun 30, 2024 | 87.64 Mn |
| Mar 31, 2024 | 91.06 Mn |
| Dec 31, 2023 | 95.08 Mn |
| Sep 30, 2023 | 97.42 Mn |
| Jun 30, 2023 | 98.50 Mn |
| Mar 31, 2023 | 96.62 Mn |
| Dec 31, 2022 | 104.31 Mn |
| Sep 30, 2022 | 157.24 Mn |
| Jun 30, 2022 | 153.63 Mn |
| Mar 31, 2022 | 190.85 Mn |
| Dec 31, 2021 | 197.62 Mn |
| Sep 30, 2021 | 211.86 Mn |